HC Wainwright Issues Pessimistic Estimate for EVAX Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Analysts at HC Wainwright cut their FY2027 EPS estimates for Evaxion Biotech A/S in a research report issued on Wednesday, April 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.12 per share for the year, down from their previous forecast of $0.13. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.09 EPS.

Separately, Lake Street Capital lowered their target price on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th.

Evaxion Biotech A/S Stock Down 10.7 %

Shares of NASDAQ EVAX opened at $1.51 on Friday. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The company has a market cap of $1.77 million, a P/E ratio of -1.04 and a beta of -0.25. Evaxion Biotech A/S has a 52 week low of $1.50 and a 52 week high of $22.05. The business has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $6.74.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Tuesday, April 1st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.19. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.66 million.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent filing with the SEC. 11.04% of the stock is currently owned by institutional investors and hedge funds.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.